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Background and Aims: It is axiomatic that all alcohol-related death
is preventable. Furthermore, 1/3 of all deaths from liver disease are
attributed to alcohol, and these deaths are increasing. One reason for
this is that alcohol-related liver disease (ARLD) remains under-
recognised and undertreated. We suggest that early detection by
means of fibroelastography (FE) in alcohol treatment clinics (ATC) is
an ideal opportunity for early detection of ARLD in a high risk
population with no previous diagnosis.
Aim: To determine the clinical utility and patient acceptability of FE
to identify the presence of liver fibrosis.
Method: An observational prospective clinical audit. The primary
outcome was to detect the presence of fibrosis using FE, and a
secondary outcome was to measure FE change over time related to
alcohol consumption. Patients were also asked to complete a
satisfaction survey including a question “Did knowing your fibroscan
result encourage you to reduce or stop drinking”. Participants: Acute
hospital, ATC patients attending for treatment of an alcohol-use
disorder with no previous history of ARLD.
Results: Of the 428 patients screened Dec 2015 – Sept 2017; 314 had
no evidence for fibrosis with a Kpa score <8, 47 had a score ≥8 and
<12, 19 had a score ≥12, <19.4 and 48 had a score ≥19.5. Sixty-three
participants had FE at baseline and six month follow-up. At baseline,
patients had an average daily consumption of 18.2 (SD = 10.5) UK
units and a mean FE result of 11.9Kpa (SD = 11.9); F0-1 = 30, F1-2 = 15,
F2-3 = 7, F3-4 = 11. At six months, there was a positive relationship
between units consumed and FE result, such that a reduction in units
was associatedwith a decrease FE score (B = 0.36, 95%CI = 0.16 to 0.57;
p = 0.01). Of 120 patients surveyed 117 stated that knowing the FE
score helped motivate them to reduce their drinking.
Conclusion: Nurse-led ATC setting is a valuable and effective setting
for the early detection of ARLD utilising FE. Importantly, we identified
67 patientswith an FE score consistentwith cirrhosis and no previous
history of ARLD. Furthermore, reductions in alcohol consumption
were associated with reductions in fibrosis. The FE score is therefore
potentially useful as an objectivemeasure for comparisons over time,
and perhaps more importantly is a useful clinical tool for patient
feedback in motivation to reduce/stop drinking, and provides
objective evidence for the positive effects of alcohol reduced
drinking.
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Background and Aims: Hepatocellular carcinoma is a significant
public health problem with an annual incidence of 16.4/100,000
adults. In a context of constant healthcare adaptation, the manage-
ment of these patients has been revamped. The notion of “care
pathway” has been introduced and led to the creation of new
positions such as complex care pathway coordinating nurses. We
wanted to determinewhether the presence of the coordinating nurse
improves care efficiency for patients with hepatocellular carcinoma
treated with chemoembolization.
Method: A comparative and retrospective cohort pilot study was
carried out in two french university hospitals. The coordinating nurse
position was effective in center A but not in center B. Clinical and
coded medical data from 107 patients with hepatocellular carcinoma
and treated for the first time with trans-arterial chemoembolization
(TACE) between January 1rst, 2015 and January 31rst, 2015 were
collected (center A: 62/center B: 45). Center Awas using twodifferent
approaches for TACE (DC Beads and lipiodol), whilst center B only
lipiodol TACE. Therewas no significant difference observed regarding
tumor features: the average tumor sizewas 4.68 ± 3.08 cm in center A
and 3.60 ± 3.56 cm in center B. The average number of nodules was
2.95 ± 2.01 in center A and 2.47 ± 1.46 in center B. All treated patients
were Child A or B7. Higher proportion of Child B patients were
observed in center B compared to center A (37.8% and 19.4%
respectively).
Results: Univariate then multivariate analysis, adjusted for possible
confounding factors such as disease stages, showed that the average
length of stay in hospital of patients hospitalized for their treatment
was significantly shorter in the centerwith coordinating nurses: 2.98
± 1.91 days in center Avs. 4.67 ± 4.25 days in center B (p = 0.01). There
was no significant difference for re-admissions and early emergen-
cies. No differences were observed regarding tumor features,
patients’ characteristics or treatment approaches.
Conclusion: The anticipation and regulation missions of the
coordinating nurse may contribute to improving care efficiency.
However, a center effect cannot be excluded. These results will be
confirmed by a planned prospective multicentric study. Interesting
results from such studies can promote the nursing role in our health
system while the position of advanced practice nurse soon to be
implemented in France.
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